BACKGROUND: There is scant evidence to guide the management of patients after hepatic artery embolization (HAE). We examined length of stay (LOS), laboratory patterns, medication usage, morbidity, and mortality of patients hospitalized after HAE for metastatic neuroendocrine tumors. METHODS: Data were abstracted retrospectively from electronic medical records on LOS, liver function tests (LFTs), i.v. antibiotics, analgesia, peak temperature, bacteremia, hepatic abscess formation, carcinoid crisis, and metastatic burden on cross-sectional imaging. RESULTS: In 2005-2009, 72 patients underwent 174 HAEs for carcinoid and islet cell tumors. The median LOS was 4 days (range, 1-8 days). There was no correlation between peak LFTs and tumor burden. Declines in LFTs were not uniform before hospital discharge; 25%, 37%, 30%, 53%, and 67% of patients were discharged before their respective aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and total and direct bilirubin levels began to decline, with no readmissions for acute hepatic failure. The median i.v. analgesia dose was 60 mg oral morphine equivalents (range, 3-1,961 mg). Pre-HAE i.v. antibiotics were administered in 99% of cases; post-HAE fever occurred in 37% of patients, with no documented bacteremia. One patient developed a hepatic abscess after HAE. There were two carcinoid crises. The single in-hospital death was associated with air in the portal veins. CONCLUSIONS: The duration and intensity of in-hospital care following HAE should be managed on an individual basis. A downward trend in LFTs is not required before discharge. Modest use of i.v. analgesia suggests that many patients could exclusively receive oral analgesics. Given the rarity of serious complications, hospital stays could be shortened, thereby reducing costs and nosocomial risks.
BACKGROUND: There is scant evidence to guide the management of patients after hepatic artery embolization (HAE). We examined length of stay (LOS), laboratory patterns, medication usage, morbidity, and mortality of patients hospitalized after HAE for metastatic neuroendocrine tumors. METHODS: Data were abstracted retrospectively from electronic medical records on LOS, liver function tests (LFTs), i.v. antibiotics, analgesia, peak temperature, bacteremia, hepatic abscess formation, carcinoid crisis, and metastatic burden on cross-sectional imaging. RESULTS: In 2005-2009, 72 patients underwent 174 HAEs for carcinoid and islet cell tumors. The median LOS was 4 days (range, 1-8 days). There was no correlation between peak LFTs and tumor burden. Declines in LFTs were not uniform before hospital discharge; 25%, 37%, 30%, 53%, and 67% of patients were discharged before their respective aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and total and direct bilirubin levels began to decline, with no readmissions for acute hepatic failure. The median i.v. analgesia dose was 60 mg oral morphine equivalents (range, 3-1,961 mg). Pre-HAE i.v. antibiotics were administered in 99% of cases; post-HAE fever occurred in 37% of patients, with no documented bacteremia. One patient developed a hepatic abscess after HAE. There were two carcinoid crises. The single in-hospital death was associated with air in the portal veins. CONCLUSIONS: The duration and intensity of in-hospital care following HAE should be managed on an individual basis. A downward trend in LFTs is not required before discharge. Modest use of i.v. analgesia suggests that many patients could exclusively receive oral analgesics. Given the rarity of serious complications, hospital stays could be shortened, thereby reducing costs and nosocomial risks.
Authors: Huda S Salman; Jacov Cynamon; Marci Jagust; Curtis Bakal; Alla Rozenblit; Ron Kaleya; Abdissa Negassa; Scott Wadler Journal: Clin Colorectal Cancer Date: 2002-11 Impact factor: 4.481
Authors: Sanjay Gupta; James C Yao; Kamran Ahrar; Michael J Wallace; Frank A Morello; David C Madoff; Ravi Murthy; Marshall E Hicks; Jaffer A Ajani Journal: Cancer J Date: 2003 Jul-Aug Impact factor: 3.360
Authors: Raymond H Thornton; Anne Covey; Elena N Petre; Elyn R Riedel; Mary A Maluccio; Constantinos T Sofocleous; Lynn A Brody; George I Getrajdman; Michael D'Angelica; Yuman Fong; Karen T Brown Journal: Cancer Date: 2009-11-01 Impact factor: 6.860
Authors: Alexander S Ho; Joel Picus; Michael D Darcy; Benjamin Tan; Jennifer E Gould; Thomas K Pilgram; Daniel B Brown Journal: AJR Am J Roentgenol Date: 2007-05 Impact factor: 3.959
Authors: G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann Journal: Virchows Arch Date: 2006-09-12 Impact factor: 4.064
Authors: Nicholas Fidelman; Robert K Kerlan; Randall A Hawkins; Miguel Pampaloni; Andrew G Taylor; Maureen P Kohi; K Pallav Kolli; Chloe E Atreya; Emily K Bergsland; R Kate Kelley; Andrew H Ko; W Michael Korn; Katherine Van Loon; Ryan M McWhirter; Jennifer Luan; Curt Johanson; Alan P Venook Journal: J Gastrointest Oncol Date: 2016-12
Authors: Jill K Onesti; Lawrence A Shirley; Neil D Saunders; Gail W Davidson; Mary E Dillhoff; Hooman Khabiri; Gregory E Guy; Joshua D Dowell; Carl R Schmidt; Manisha H Shah; Mark Bloomston Journal: J Gastrointest Surg Date: 2015-10-21 Impact factor: 3.452
Authors: Nicholas Fidelman; Robert K Kerlan; Randall A Hawkins; Andrew G Taylor; Maureen P Kohi; K Pallav Kolli; Emily K Bergsland; R Kate Kelley; Andrew H Ko; W Michael Korn; Ryan M McWhirter; Jennifer Luan; Alan P Venook Journal: J Gastrointest Cancer Date: 2014-06
Authors: Jessica E Maxwell; Boris Naraev; Daniel M Halperin; Michael A Choti; Thorvardur R Halfdanarson Journal: Ann Surg Oncol Date: 2022-02-14 Impact factor: 5.344